



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent
Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Endothelial Keratoplasty

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 180

BCBSA Reference Number: 9.03.22 (For Plan internal use only)

NCD/LCD: N/A

Related Policies

- Keratoprosthesis, #[221](#)
- Optical Coherence Tomography of the Anterior Eye Segment, #[084](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Endothelial keratoplasty [Descemet's stripping endothelial keratoplasty (DSEK) Descemet's stripping automated endothelial keratoplasty (DSAEK)], Descemet's membrane endothelial keratoplasty [DMEK], or Descemet's membrane automated endothelial keratoplasty [DMAEK]) may be considered **MEDICALLY NECESSARY** for the treatment of endothelial dysfunction, including but not limited to:

- Ruptures in Descemet's membrane,
- Endothelial dystrophy,
- Aphakic and pseudophakic bullous keratopathy,
- Iridocorneal endothelial (ICE) syndrome,
- Corneal edema attributed to endothelial failure, or
- Failure or rejection of a previous corneal transplant.

Femtosecond laser-assisted corneal endothelial keratoplasty (FLEK) or femtosecond and excimer lasers-assisted endothelial keratoplasty (FELEK) are **INVESTIGATIONAL**.

Endothelial keratoplasty is **NOT MEDICALLY NECESSARY** when endothelial dysfunction is not the primary cause of decreased corneal clarity.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .
Commercial PPO and Indemnity	Prior authorization is not required .
Medicare HMO BlueSM	Prior authorization is not required .
Medicare PPO BlueSM	Prior authorization is not required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
65756	Keratoplasty (corneal transplant); endothelial
65757	Backbench preparation of corneal endothelial allograft prior to transplantation (List separately in addition to code for primary procedure)

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT codes above if medical necessity criteria are met:

ICD-10 Diagnosis Codes

ICD-10-CM Diagnosis codes:	Code Description
H18.10	Bullous keratopathy, unspecified eye
H18.11	Bullous keratopathy, right eye
H18.12	Bullous keratopathy, left eye
H18.13	Bullous keratopathy, bilateral
H18.20	Unspecified corneal edema
H18.211	Corneal edema secondary to contact lens, right eye
H18.212	Corneal edema secondary to contact lens, left eye
H18.213	Corneal edema secondary to contact lens, bilateral
H18.219	Corneal edema secondary to contact lens, unspecified eye
H18.221	Idiopathic corneal edema, right eye
H18.222	Idiopathic corneal edema, left eye
H18.223	Idiopathic corneal edema, bilateral
H18.229	Idiopathic corneal edema, unspecified eye

H18.231	Secondary corneal edema, right eye
H18.232	Secondary corneal edema, left eye
H18.233	Secondary corneal edema, bilateral
H18.239	Secondary corneal edema, unspecified eye
H18.331	Rupture in Descemet's membrane, right eye
H18.332	Rupture in Descemet's membrane, left eye
H18.333	Rupture in Descemet's membrane, bilateral
H18.339	Rupture in Descemet's membrane, unspecified eye
H18.511	Endothelial corneal dystrophy, right eye
H18.512	Endothelial corneal dystrophy, left eye
H18.513	Endothelial corneal dystrophy, bilateral
H18.519	Endothelial corneal dystrophy, unspecified eye
H18.591	Other hereditary corneal dystrophies, right eye
H18.592	Other hereditary corneal dystrophies, left eye
H18.593	Other hereditary corneal dystrophies, bilateral
H18.599	Other hereditary corneal dystrophies, unspecified eye
T86.8401	Corneal transplant rejection, right eye
T86.8402	Corneal transplant rejection, left eye
T86.8403	Corneal transplant rejection, bilateral
T86.8409	Corneal transplant rejection, unspecified eye
T86.8411	Corneal transplant failure, right eye
T86.8412	Corneal transplant failure, left eye
T86.8413	Corneal transplant failure, bilateral
T86.8419	Corneal transplant failure, unspecified eye
T85.21XA	Breakdown (mechanical) of intraocular lens, initial encounter
T85.22XA	Displacement of intraocular lens, initial encounter
T85.29XA	Other mechanical complication of intraocular lens, initial encounter

Description

Corneal Disease

The cornea, a clear, dome-shaped membrane that covers the front of the eye, is a key refractive element for vision. Layers of the cornea consist of the epithelium (outermost layer); Bowman layer; the stroma, which comprises approximately 90% of the cornea; Descemet membrane; and the endothelium. The endothelium removes fluid from and limits fluid into the stroma, thereby maintaining the ordered arrangement of collagen and preserving the cornea's transparency. Diseases that affect the endothelial layer include Fuchs endothelial dystrophy, aphakic and pseudophakic bullous keratopathy (corneal edema following cataract extraction), and failure or rejection of a previous corneal transplant.

Treatment

The established surgical treatment for corneal disease is penetrating keratoplasty, which involves the creation of a large central opening through the cornea and then filling the opening with full-thickness donor cornea that is sutured in place. Visual recovery after penetrating keratoplasty may take 1 year or more due to slow wound healing of the avascular full-thickness incision, and the procedure frequently results in irregular astigmatism due to sutures and the full-thickness vertical corneal wound. Penetrating keratoplasty is associated with an increased risk of wound dehiscence, endophthalmitis, and total visual loss after relatively minor trauma for years after the index procedure. There is also the risk of severe, sight-threatening complications such as expulsive suprachoroidal hemorrhage, in which the ocular contents are expelled during the operative procedure, as well as postoperative catastrophic wound failure.

A number of related techniques have been, or are being, developed to selectively replace the diseased endothelial layer. One of the first endothelial keratoplasty techniques was termed *deep lamellar endothelial keratoplasty*, which used a smaller incision than penetrating keratoplasty, allowed more rapid

visual rehabilitation, and reduced postoperative irregular astigmatism and suture complications. Modified endothelial keratoplasty techniques include endothelial lamellar keratoplasty, endokeratoplasty, posterior corneal grafting, and microkeratome-assisted posterior keratoplasty. Most frequently used at this time are Descemet stripping endothelial keratoplasty, which uses hand-dissected donor tissue, and Descemet stripping automated endothelial keratoplasty, which uses an automated microkeratome to assist in donor tissue dissection. These techniques include donor stroma along with the endothelium and Descemet membrane, which results in a thickened stromal layer after transplantation. If the donor tissue comprises Descemet membrane and endothelium alone, the technique is known as Descemet membrane endothelial keratoplasty. By eliminating the stroma on the donor tissue and possibly reducing stromal interface haze, Descemet membrane endothelial keratoplasty is considered a potential improvement over Descemet stripping endothelial keratoplasty and Descemet stripping automated endothelial keratoplasty. A variation of Descemet membrane endothelial keratoplasty is Descemet membrane automated endothelial keratoplasty. Descemet membrane automated endothelial keratoplasty contains a stromal rim of tissue at the periphery of the Descemet membrane endothelial keratoplasty graft to improve adherence and improve handling of the donor tissue. A laser may also be used for stripping in a procedure called femtosecond laser-assisted endothelial keratoplasty and femtosecond and excimer laser-assisted endothelial keratoplasty.

Endothelial keratoplasty involves removal of the diseased host endothelium and Descemet membrane with special instruments through a small peripheral incision. A donor tissue button is prepared from the corneoscleral tissue after removing the anterior donor corneal stroma by hand (eg, Descemet stripping endothelial keratoplasty) or with the assistance of an automated microkeratome (eg, Descemet stripping automated endothelial keratoplasty) or laser (femtosecond laser-assisted endothelial keratoplasty or femtosecond and excimer laser-assisted endothelial keratoplasty). Donor tissue preparation may be performed by the surgeon in the operating room or by the eye bank and then transported to the operating room for final punch out of the donor tissue button. For minimal endothelial damage, the donor tissue must be carefully positioned in the anterior chamber. An air bubble is frequently used to center the donor tissue and facilitate adhesion between the stromal side of the donor lenticule and the host posterior corneal stroma. Repositioning of the donor tissue with the application of another air bubble may be required in the first week if the donor tissue dislocates. The small corneal incision is closed with 1 or more sutures, and steroids or immune-suppressants may be provided topically or orally to reduce the potential for graft rejection. Visual recovery following endothelial keratoplasty is typically 4 to 8 weeks.

Eye Bank Association of America statistics have shown the number of endothelial keratoplasty cases in the United States increased from 30710 in 2015 to 32221 in 2016.¹ The Eye Bank Association of America estimated that, as of 2016, nearly 40% of corneal transplants performed in the United States were endothelial grafts. As with any new surgical technique, questions have been posed about long-term efficacy and risk of complications. Endothelial keratoplasty-specific complications include graft dislocations, endothelial cell loss, and rate of failed grafts. Long-term complications include increased intraocular pressure, graft rejection, and late endothelial failure.

Summary

Endothelial keratoplasty also referred to as posterior lamellar keratoplasty, is a form of corneal transplantation in which the diseased inner layer of the cornea, the endothelium, is replaced with healthy donor tissue. Specific techniques include Descemet stripping endothelial keratoplasty, Descemet stripping automated endothelial keratoplasty, Descemet membrane endothelial keratoplasty, and Descemet membrane automated endothelial keratoplasty. Endothelial keratoplasty, and particularly Descemet stripping endothelial keratoplasty, Descemet stripping automated endothelial keratoplasty, Descemet membrane endothelial keratoplasty, and Descemet membrane automated endothelial keratoplasty, are becoming standard procedures. Femtosecond laser-assisted endothelial keratoplasty and femtosecond and excimer laser-assisted endothelial keratoplasty have also been reported as alternatives to prepare the donor endothelium.

For individuals who have endothelial disease of the cornea who receive Descemet stripping endothelial keratoplasty or Descemet stripping automated endothelial keratoplasty, the evidence includes a number of cohort studies, a randomized controlled trial (RCT), and systematic reviews. Relevant outcomes are

change in disease status, morbid events, and functional outcomes. The available literature has indicated that these procedures improve visual outcomes and reduce serious complications associated with penetrating keratoplasty. Specifically, visual recovery occurs much earlier. Because endothelial keratoplasty maintains an intact globe without a sutured donor cornea, astigmatism or the risk of severe, sight-threatening complications such as expulsive suprachoroidal hemorrhage and postoperative catastrophic wound failure are eliminated. The Descemet Endothelial Thickness Comparison Trial (DETECT) RCT reported improved visual acuity outcomes with Descemet membrane endothelial keratoplasty compared to ultra-thin Descemet stripping automated endothelial keratoplasty. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have endothelial disease of the cornea who receive Descemet membrane endothelial keratoplasty or Descemet membrane automated endothelial keratoplasty, the evidence includes a number of cohort studies and systematic reviews. Relevant outcomes are change in disease status, morbid events, and functional outcomes. Evidence from the cohort studies and meta-analyses has consistently shown that the use of Descemet membrane endothelial keratoplasty and Descemet membrane automated endothelial keratoplasty procedures improve visual acuity. When compared with Descemet stripping endothelial keratoplasty and Descemet stripping automated endothelial keratoplasty, Descemet membrane endothelial keratoplasty and Descemet membrane automated endothelial keratoplasty showed significantly greater improvements in visual acuity, both in the short term and through 1 year of follow-up. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have endothelial disease of the cornea who receive femtosecond laser-assisted endothelial keratoplasty and femtosecond and excimer laser-assisted endothelial keratoplasty, the evidence includes a multicenter RCT and a systematic review comparing femtosecond laser-assisted endothelial keratoplasty with penetrating keratoplasty, and an RCT comparing femtosecond-prepared Descemet stripping automated endothelial keratoplasty to microkeratome-prepared Descemet membrane automated endothelial keratoplasty. Relevant outcomes are change in disease status, morbid events, and functional outcomes. There were conflicting results in the evidence regarding mean best-corrected visual acuity and endothelial cell loss after femtosecond laser-assisted endothelial keratoplasty versus penetrating keratoplasty. With the exception of dislocation and need for repositioning of the femtosecond laser-assisted endothelial keratoplasty, the percentage of complications was similar between groups. Complications in the femtosecond laser-assisted endothelial keratoplasty group were due to pupillary block, graft failure, epithelial ingrowth, and elevated intraocular pressure, whereas complications in the penetrating keratoplasty group were related to sutures and elevated intraocular pressure. Worsened visual acuity and a 100% graft dislocation rate were reported for femtosecond-prepared Descemet stripping automated endothelial keratoplasty compared to 0% in manually-prepared Descemet stripping automated endothelial keratoplasty. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
4/2022	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
4/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
10/2020	Clarified coding information
5/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
4/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
4/2018	Annual policy review. Description, summary, and references updated. Policy statements unchanged.

2/2018	Clarified coding information.
10/2017	Annual policy review. New references added.
4/2016	Annual policy review. New references added.
11/2015	Added coding language.
5/2014	Updated Coding section with ICD10 procedure and diagnosis codes. Effective 10/2015.
3/2014	Annual policy review. New medically necessary, not medically necessary and investigational indications described. Effective 3/1/2014. Clarified coding information.
1/2014	Clarified coding information.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
2/2011	Reviewed - Medical Policy Group – Psychiatry and Ophthalmology. No changes to policy statements.
5/1/2010	Medical Policy #180 effective 5/1/2010 created.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Eye Bank Association of America. 2019 Eye Banking Statistical Report. 2019; <https://restoresight.org/wp-content/uploads/2020/04/2019-EBAA-Stat-Report-FINAL.pdf>. Accessed February 1, 2022.
2. Dunker SL, Dickman MM, Wisse RPL, et al. Descemet Membrane Endothelial Keratoplasty versus Ultrathin Descemet Stripping Automated Endothelial Keratoplasty: A Multicenter Randomized Controlled Clinical Trial. *Ophthalmology*. Sep 2020; 127(9): 1152-1159. PMID 32386811
3. Woo JH, Ang M, Htoon HM, et al. Descemet Membrane Endothelial Keratoplasty Versus Descemet Stripping Automated Endothelial Keratoplasty and Penetrating Keratoplasty. *Am J Ophthalmol*. Nov 2019; 207: 288-303. PMID 31228467
4. Lee WB, Jacobs DS, Musch DC, et al. Descemet's stripping endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology. *Ophthalmology*. Sep 2009; 116(9): 1818-30. PMID 19643492
5. Stuart AJ, Romano V, Virgili G, et al. Descemet's membrane endothelial keratoplasty (DMEK) versus Descemet's stripping automated endothelial keratoplasty (DSAEK) for corneal endothelial failure. *Cochrane Database Syst Rev*. Jun 25 2018; 6: CD012097. PMID 29940078
6. Marques RE, Guerra PS, Sousa DC, et al. DMEK versus DSAEK for Fuchs' endothelial dystrophy: A meta-analysis. *Eur J Ophthalmol*. Jan 2019; 29(1): 15-22. PMID 29661044
7. Chamberlain W, Lin CC, Austin A, et al. Descemet Endothelial Thickness Comparison Trial: A Randomized Trial Comparing Ultrathin Descemet Stripping Automated Endothelial Keratoplasty with Descemet Membrane Endothelial Keratoplasty. *Ophthalmology*. Jan 2019; 126(1): 19-26. PMID 29945801
8. Duggan MJ, Rose-Nussbaumer J, Lin CC, et al. Corneal Higher-Order Aberrations in Descemet Membrane Endothelial Keratoplasty versus Ultrathin DSAEK in the Descemet Endothelial Thickness Comparison Trial: A Randomized Clinical Trial. *Ophthalmology*. Jul 2019; 126(7): 946-957. PMID 30776384
9. Hirabayashi KE, Chamberlain W, Rose-Nussbaumer J, et al. Corneal Light Scatter After Ultrathin Descemet Stripping Automated Endothelial Keratoplasty Versus Descemet Membrane Endothelial Keratoplasty in Descemet Endothelial Thickness Comparison Trial: A Randomized Controlled Trial. *Cornea*. Jun 2020; 39(6): 691-696. PMID 31939923

10. Fuest M, Ang M, Htoon HM, et al. Long-term Visual Outcomes Comparing Descemet Stripping Automated Endothelial Keratoplasty and Penetrating Keratoplasty. *Am J Ophthalmol.* Oct 2017; 182: 62-71. PMID 28739420
11. Heinzelmann S, Bohringer D, Eberwein P, et al. Outcomes of Descemet membrane endothelial keratoplasty, Descemet stripping automated endothelial keratoplasty and penetrating keratoplasty from a single centre study. *Graefes Arch Clin Exp Ophthalmol.* Mar 2016; 254(3): 515-22. PMID 26743748
12. Wacker K, Baratz KH, Maguire LJ, et al. Descemet Stripping Endothelial Keratoplasty for Fuchs' Endothelial Corneal Dystrophy: Five-Year Results of a Prospective Study. *Ophthalmology.* Jan 2016; 123(1): 154-60. PMID 26481820
13. Li JY, Terry MA, Goshe J, et al. Three-year visual acuity outcomes after Descemet's stripping automated endothelial keratoplasty. *Ophthalmology.* Jun 2012; 119(6): 1126-9. PMID 22364863
14. Dapena I, Ham L, Melles GR. Endothelial keratoplasty: DSEK/DSAEK or DMEK--the thinner the better?. *Curr Opin Ophthalmol.* Jul 2009; 20(4): 299-307. PMID 19417653
15. Rose L, Kelliher C, Jun AS. Endothelial keratoplasty: historical perspectives, current techniques, future directions. *Can J Ophthalmol.* Aug 2009; 44(4): 401-5. PMID 19606160
16. Deng SX, Lee WB, Hammersmith KM, et al. Descemet Membrane Endothelial Keratoplasty: Safety and Outcomes: A Report by the American Academy of Ophthalmology. *Ophthalmology.* Feb 2018; 125(2): 295-310. PMID 28923499
17. Singh A, Zarei-Ghanavati M, Avadhanam V, et al. Systematic Review and Meta-Analysis of Clinical Outcomes of Descemet Membrane Endothelial Keratoplasty Versus Descemet Stripping Endothelial Keratoplasty/Descemet Stripping Automated Endothelial Keratoplasty. *Cornea.* Nov 2017; 36(11): 1437-1443. PMID 28834814
18. Pavlovic I, Shajari M, Herrmann E, et al. Meta-Analysis of Postoperative Outcome Parameters Comparing Descemet Membrane Endothelial Keratoplasty Versus Descemet Stripping Automated Endothelial Keratoplasty. *Cornea.* Dec 2017; 36(12): 1445-1451. PMID 28957976
19. Li S, Liu L, Wang W, et al. Efficacy and safety of Descemet's membrane endothelial keratoplasty versus Descemet's stripping endothelial keratoplasty: A systematic review and meta-analysis. *PLoS One.* 2017; 12(12): e0182275. PMID 29252983
20. Wu J, Wu T, Li J, et al. DSAEK or DMEK for failed penetrating keratoplasty: a systematic review and single-arm meta-analysis. *Int Ophthalmol.* Jul 2021; 41(7): 2315-2328. PMID 34117964
21. Oellerich S, Baydoun L, Peraza-Nieves J, et al. Multicenter Study of 6-Month Clinical Outcomes After Descemet Membrane Endothelial Keratoplasty. *Cornea.* Dec 2017; 36(12): 1467-1476. PMID 28957979
22. Tourtas T, Laaser K, Bachmann BO, et al. Descemet membrane endothelial keratoplasty versus descemet stripping automated endothelial keratoplasty. *Am J Ophthalmol.* Jun 2012; 153(6): 1082-90.e2. PMID 22397955
23. van Dijk K, Ham L, Tse WH, et al. Near complete visual recovery and refractive stability in modern corneal transplantation: Descemet membrane endothelial keratoplasty (DMEK). *Cont Lens Anterior Eye.* Feb 2013; 36(1): 13-21. PMID 23108011
24. Ham L, Dapena I, van Luijk C, et al. Descemet membrane endothelial keratoplasty (DMEK) for Fuchs endothelial dystrophy: review of the first 50 consecutive cases. *Eye (Lond).* Oct 2009; 23(10): 1990-8. PMID 19182768
25. Dapena I, Ham L, Droutsas K, et al. Learning Curve in Descemet's Membrane Endothelial Keratoplasty: First Series of 135 Consecutive Cases. *Ophthalmology.* Nov 2011; 118(11): 2147-54. PMID 21777980
26. Price MO, Giebel AW, Fairchild KM, et al. Descemet's membrane endothelial keratoplasty: prospective multicenter study of visual and refractive outcomes and endothelial survival. *Ophthalmology.* Dec 2009; 116(12): 2361-8. PMID 19875170
27. Guerra FP, Anshu A, Price MO, et al. Descemet's membrane endothelial keratoplasty: prospective study of 1-year visual outcomes, graft survival, and endothelial cell loss. *Ophthalmology.* Dec 2011; 118(12): 2368-73. PMID 21872938
28. Anshu A, Price MO, Price FW. Risk of corneal transplant rejection significantly reduced with Descemet's membrane endothelial keratoplasty. *Ophthalmology.* Mar 2012; 119(3): 536-40. PMID 22218143

29. McCauley MB, Price MO, Fairchild KM, et al. Prospective study of visual outcomes and endothelial survival with Descemet membrane automated endothelial keratoplasty. *Cornea*. Mar 2011; 30(3): 315-9. PMID 21099412
30. Liu Y, Li X, Li W, et al. Systematic review and meta-analysis of femtosecond laser-enabled keratoplasty versus conventional penetrating keratoplasty. *Eur J Ophthalmol*. May 2021; 31(3): 976-987. PMID 32223431
31. Ivarsen A, Hjortdal J. Clinical outcome of Descemet's stripping endothelial keratoplasty with femtosecond laser-prepared grafts. *Acta Ophthalmol*. Aug 2018; 96(5): e655-e656. PMID 29372934
32. Cheng YY, Schouten JS, Tahzib NG, et al. Efficacy and safety of femtosecond laser-assisted corneal endothelial keratoplasty: a randomized multicenter clinical trial. *Transplantation*. Dec 15 2009; 88(11): 1294-302. PMID 19996929
33. Sorkin N, Mednick Z, Einan-Lifshitz A, et al. Three-Year Outcome Comparison Between Femtosecond Laser-Assisted and Manual Descemet Membrane Endothelial Keratoplasty. *Cornea*. Jul 2019; 38(7): 812-816. PMID 30973405
34. Singhal D, Maharana PK. RE: "Three-Year Outcome Comparison Between Femtosecond Laser-Assisted and Manual Descemet Membrane Endothelial Keratoplasty". *Cornea*. Nov 2019; 38(11): e51. PMID 31414998
35. Hosny MH, Marrie A, Karim Sidky M, et al. Results of Femtosecond Laser-Assisted Descemet Stripping Automated Endothelial Keratoplasty. *J Ophthalmol*. 2017; 2017: 8984367. PMID 28695004
36. Vetter JM, Butsch C, Faust M, et al. Irregularity of the posterior corneal surface after curved interface femtosecond laser-assisted versus microkeratome-assisted descemet stripping automated endothelial keratoplasty. *Cornea*. Feb 2013; 32(2): 118-24. PMID 23132446
37. Trinh L, Saubamea B, Auclin F, et al. A new technique of endothelial graft: the femtosecond and excimer lasers-assisted endothelial keratoplasty (FELEK). *Acta Ophthalmol*. Sep 2013; 91(6): e497-9. PMID 23607667
38. National Institute for Health and Care Excellence (NICE). Corneal endothelial transplantation [IPG304]. 2009; <https://www.nice.org.uk/guidance/IPG304>. Accessed February 1, 2022.